Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
AstraZeneca
UBS
Dow
Merck
Teva
Accenture
US Army
Cantor Fitzgerald
McKinsey

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204065

« Back to Dashboard
NDA 204065 describes DESVENLAFAXINE SUCCINATE, which is a drug marketed by Alembic Pharms Ltd, Zydus Pharms Usa Inc, Sandoz Inc, Actavis Labs Fl, Lupin Ltd, West-ward Pharms Int, and Mylan Pharms Inc, and is included in eight NDAs. It is available from six suppliers. Additional details are available on the DESVENLAFAXINE SUCCINATE profile page.

The generic ingredient in DESVENLAFAXINE SUCCINATE is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.

Summary for NDA: 204065

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 204065

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL 204065 ANDA Actavis Pharma, Inc. 0591-3659 0591-3659-10 1000 TABLET, EXTENDED RELEASE in 1 BOTTLE (0591-3659-10)
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL 204065 ANDA Actavis Pharma, Inc. 0591-3659 0591-3659-19 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (0591-3659-19)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 25MG BASE
Approval Date:Jul 29, 2016TE:ABRLD:No
Regulatory Exclusivity Expiration:Jan 25, 2017
Regulatory Exclusivity Use:PATENT CHALLENGE

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 50MG BASE
Approval Date:Jul 29, 2016TE:ABRLD:No
Regulatory Exclusivity Expiration:Aug 28, 2017
Regulatory Exclusivity Use:PATENT CHALLENGE

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 100MG BASE
Approval Date:Jul 29, 2016TE:ABRLD:No
Regulatory Exclusivity Expiration:Aug 28, 2017
Regulatory Exclusivity Use:PATENT CHALLENGE


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Julphar
Moodys
Harvard Business School
Teva
Covington
AstraZeneca
Medtronic
Queensland Health
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot